As per MRFR analysis, the US Allergy Immunotherapy Market Size was estimated at 1.12 (USD Billion) in 2023. The US Allergy Immunotherapy Market Industry is expected to grow from 1.2 (USD Billion) in 2024 to 2.62 (USD Billion) by 2035. The US Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 7.383% during the forecast period (2025 - 2035).
The US Allergy Immunotherapy Market is witnessing significant evolution influenced by a variety of trends and market drivers. A key market driver is the increasing prevalence of allergic diseases in the United States, which is pushing more individuals toward seeking effective treatment options. According to health reports, allergy conditions like hay fever, asthma, and other respiratory allergies affect millions of Americans, making immunotherapy a sought-after solution.
Furthermore, advancements in treatment methodologies, such as sublingual immunotherapy (SLIT) and innovative delivery systems, are making therapy more accessible and appealing to patients. In recent times, there's a noticeable shift toward personalized medicine in allergy management, with immunotherapy being tailored to individual patient needs. This trend aligns with broader healthcare statistics and initiatives emphasizing personalized approaches to improve treatment outcomes and patient satisfaction.
The growing awareness of the benefits of immunotherapy among both healthcare providers and patients serves as a prime opportunity that can be further explored in the market. Additionally, the increasing role of telemedicine in the healthcare system, especially post-pandemic, has provided new avenues for allergy sufferers to access consultations and treatment plans that include immunotherapy. Patients are increasingly seeking virtual consultations, which can simplify the path to receiving allergy treatments, including immunotherapy.
This shift reflects how the US healthcare landscape is adapting to modern patient needs, making it essential for allergy immunotherapy providers to embrace these changes to capture a larger share of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The prevalence of allergic conditions, including allergic rhinitis and asthma, is steadily rising in the United States, with reports indicating that around 19.8 million adults and 5.2 million children suffer from hay fever alone. The American Academy of Allergy, Asthma, and Immunology (AAAAI) reports a significant increase in cases, especially among children, highlighting a public health trend. As allergic conditions become more common, there is a heightened demand for effective treatment options, leading to growth in the US Allergy Immunotherapy Market Industry.
Additionally, environmental factors such as rising pollution levels and climate change have been linked to improving the allergy landscape, resulting in more individuals seeking immunotherapy as a viable solution.
The US Allergy Immunotherapy Market Industry is significantly benefiting from advancements in immunotherapy techniques, including sublingual and subcutaneous immunotherapy. The American College of Allergy, Asthma, and Immunology (ACAAI) emphasizes that these innovative methods are becoming increasingly effective and convenient for patients. For instance, the approval and widespread adoption of new formulations have made the administration of immunotherapy easier and more tolerable, driving market growth.
As more healthcare providers embrace these advancements, patient uptake of immunotherapy is expected to rise considerably, illustrating a positive trajectory for the US Allergy Immunotherapy Market.
In the United States, healthcare expenditure is increasing, with the Centers for Medicare and Medicaid Services (CMS) projecting healthcare spending to reach approximately USD 6.2 trillion by 2028. This increase in spending includes a growing commitment to managing chronic conditions such as allergies. Alongside this financial growth, awareness about allergy treatments, particularly immunotherapy options, is expanding.
Initiatives led by organizations like the Asthma and Allergy Foundation of America are educating patients about allergies and available treatments, driving interest and participation in allergy immunotherapy programs. This increased facilitation of resources and education is critical in propelling the US Allergy Immunotherapy Market Industry forward.
The US Allergy Immunotherapy Market is witnessing notable growth within its Type segment, characterized by various delivery methods including Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy. This segment plays a crucial role in the management of allergic conditions, with Subcutaneous Immunotherapy historically being one of the most widely used methods due to its longstanding effectiveness and comprehensive treatment protocol. Patients receive allergy shots at scheduled intervals to build their tolerance to allergens, which has made it a trusted option among healthcare providers and patients alike.
Meanwhile, Sublingual Immunotherapy has gained traction in recent years due to its ease of administration, as patients can take the medication at home under their tongues, eliminating the need for regular clinic visits associated with injections. This convenience appeals to a broader demographic, particularly among individuals who may experience anxiety about needles or those with hectic schedules. Additionally, the increasing demand for patient-friendly treatment options contributes significantly to its growth within the market.
Oral Immunotherapy, though relatively newer compared to the other methods, is recognized for its innovative approach towards allergy management. This method entails administering food allergens in gradually increasing amounts, which is vital in addressing food allergies. The rise in food allergy prevalence in the US highlights the importance of Oral Immunotherapy, making it a significant focal point within the industry. Each type of immunotherapy not only caters to specific patient needs and preferences but also illustrates the diversification within the US Allergy Immunotherapy Market, driven by the pressing need for effective and patient-centric treatments. The market continues to evolve with these therapeutic options, reflecting the overall trends of personalized medicine and patient engagement in managing allergies effectively.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Allergy Immunotherapy Market is characterized by its diverse product offerings, prominently featuring Allergen Extracts, Conventional Immunotherapy, and Biologics. Allergen Extracts remain a crucial component, as they provide the foundational basis for treatment, enabling tailored therapy based on individual patient allergies. Conventional Immunotherapy plays a significant role in the market, as it has a long-standing history and is widely adopted, helping to desensitize patients over time and alleviating symptoms through a gradual exposure approach.
Meanwhile, Biologics have emerged as a transformative segment in recent years, leveraging advancements in biotechnology to deliver targeted therapies that offer improved efficacy and safety profiles. The growing prevalence of allergic diseases in the US, compounded by environmental factors and lifestyle changes, fuels demand across these categories. Furthermore, ongoing Research and Development in the allergy treatment space presents numerous opportunities for innovation, with newer products expected to hit the market, enhancing treatment modalities and improving patient outcomes. Collectively, these segments contribute to the dynamic landscape of the US Allergy Immunotherapy Market, addressing the pressing healthcare needs of an increasingly allergenic population.
The US Allergy Immunotherapy Market demonstrates a diverse landscape within the Indication segment, which includes conditions like Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. Among these indications, Allergic Rhinitis holds a prominent position, driven by the increasing prevalence of pollen and environmental allergens in urban settings, which significantly impacts the quality of life. Allergic Asthma continues to be a major concern, with its effects on respiratory health prompting a growing demand for effective immunotherapy solutions.
Moreover, Atopic Dermatitis is gaining attention due to the rising incidence of skin allergies in children, thus making it crucial for parents to seek preventive and remedial treatments. Food Allergies present another significant aspect, as the awareness regarding allergic reactions to certain foods is escalating, pushing for innovative therapies. These indications not only shape the US Allergy Immunotherapy Market data but also reflect the necessity for tailored treatment options that cater to diverse patient needs, ensuring broad opportunities for market players aiming to enhance the quality of life of individuals affected by allergies.
The US Allergy Immunotherapy Market, categorized by Patient Type, includes diverse demographics such as Pediatric, Adult, and Geriatric populations, each exhibiting unique characteristics and needs. Pediatric patients often experience a higher prevalence of allergies, which makes early intervention crucial to manage symptoms effectively and improve quality of life. Adults typically seek immunotherapy for persistent allergic conditions, illustrating significant demand and engagement with treatment options to enhance daily functioning in professional and personal life.
Geriatric patients, on the other hand, present unique challenges due to comorbidities and polypharmacy, necessitating tailored approaches and increased awareness among healthcare providers. The growth in the US Allergy Immunotherapy Market is propelled by the rising incidence of allergies and asthma, alongside growing awareness of treatment options. This segment is increasingly significant as demographic shifts impact healthcare strategies, paving the way for innovative therapies and improved patient outcomes in the allergy management landscape. The rising acceptance of immunotherapy as a long-term solution also plays a pivotal role in shaping trends, contributing to the market's evolution in response to patient needs across all age groups.
The US Allergy Immunotherapy Market is characterized by a dynamic competitive landscape driven by the increasing prevalence of allergic conditions, advancements in immunotherapy, and the growing demand for innovative treatment options. This market is shaped by the participation of multiple players, each aiming to strengthen their foothold through differentiation, strategic partnerships, and a focus on patient-centric solutions. As the market is evolving, companies are investing heavily in research and development to create more effective and personalized immunotherapy treatments. The emphasis on patient compliance and outcomes, along with regulatory approvals, plays a crucial role in determining the competitive advantage of market players.
Stallergenes Greer has established a significant presence in the US Allergy Immunotherapy Market, primarily known for its innovative products that cater to allergic rhinitis and other allergy-related conditions. The company possesses a portfolio of sublingual immunotherapy (SLIT) products, which are designed to enhance patient convenience and improve compliance. Stallergenes Greer's strengths lie in its strong commitment to research and development, allowing it to offer advanced therapeutic solutions that meet the needs of patients and healthcare providers alike. Additionally, the company benefits from a robust distribution network that ensures accessibility of its products across various regions in the US, positioning it as a reliable player in the competitive landscape.
Novartis has been a key contributor to the US Allergy Immunotherapy Market, with a diverse range of products and services designed to address allergies through innovative treatments. The company is recognized for its significant investments in research and development, leading to breakthrough therapies that target a range of allergic reactions. Novartis offers a portfolio that includes biologics and conventional immunotherapy products, allowing it to cater to a broad spectrum of patients. The company's strengths lie not only in its robust product offerings but also in its strategic mergers and acquisitions, further strengthening its market presence. These factors, coupled with strong branding and marketing strategies, enable Novartis to maintain a competitive edge and position itself as a key player in the US allergy immunotherapy landscape.
The US Allergy Immunotherapy Market has been witnessing significant developments recently. Notably, in August 2023, Stallergenes Greer announced the expansion of their product line with a new sublingual immunotherapy treatment aimed at grass pollen allergies, which is expected to enhance patient access to allergen management. In October 2023, Aimmune Therapeutics received FDA approval for their peanut protein immunotherapy, further solidifying their position in the market. The ongoing collaboration between Merck and Regeneron Pharmaceuticals continues to advance research and development in this field, potentially leading to innovative treatment solutions.
Additionally, in June 2023, Allergy Therapeutics completed a merger with a biotechnology firm focused on developing novel therapies, which is anticipated to enhance their market presence. Market valuations for companies such as Novartis and Merck have shown upward trends, driven by increased demand for effective allergy treatments and advancements in immunotherapy techniques. The overall market for allergy immunotherapy is expected to experience substantial growth in the coming years, especially with increasing awareness about allergic conditions and the effectiveness of immunotherapy as a long-term management solution. Notable happenings include the FDA's focus on expediting approvals for novel therapies, which has fueled competitive dynamics among key players.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.12(USD Billion) |
| MARKET SIZE 2024 | 1.2(USD Billion) |
| MARKET SIZE 2035 | 2.62(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.383% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Stallergenes Greer, Novartis, Merck, Aimmune Therapeutics, Regeneron Pharmaceuticals, Boehringer Ingelheim, Allergy Therapeutics, Dynavax Technologies, Antigen Laboratories, Allergan, vTv Therapeutics, Sanofi, Taronis Fuels |
| SEGMENTS COVERED | Type, Product, Indication, Patient Type |
| KEY MARKET OPPORTUNITIES | Increased prevalence of allergies, Growth of personalized medicine, Expansion of allergy diagnostics, Rising demand for allergy treatments, Advancement in delivery methods |
| KEY MARKET DYNAMICS | rising allergy prevalence, increased awareness of immunotherapy, advancements in treatment technologies, regulatory approvals, growing demand for personalized medicine |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Allergy Immunotherapy Market is expected to be valued at 1.2 billion USD in 2024.
By 2035, the market is projected to reach a value of 2.62 billion USD.
The expected CAGR for the market from 2025 to 2035 is 7.383%.
Subcutaneous Immunotherapy is expected to have the highest value, projected at 1.08 billion USD in 2035.
Sublingual Immunotherapy is valued at 0.36 billion USD in 2024.
Key players include Stallergenes Greer, Novartis, Merck, and Aimmune Therapeutics.
The market value for Oral Immunotherapy is projected to reach 0.76 billion USD by 2035.
In 2035, Subcutaneous Immunotherapy leads with 1.08 billion USD, followed by Sublingual at 0.78 billion USD and Oral at 0.76 billion USD.
An emerging trend is the growing preference for Sublingual and Oral Immunotherapy due to convenience and ease of administration.
Challenges include regulatory hurdles and the need for extensive clinical trials to prove efficacy and safety.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
